Business Context and Reporting Period
Unicycive Therapeutics, Inc. filed a Form 8-K regarding a securities purchase agreement entered into on March 3, 2023, with the filing signed March 6, 2023. The company is developing Renazorb for hyperphosphatemia and intends to use financing proceeds to support a U.S. New Drug Application and, if approved, commercial launch.
Transaction and Key Financial Terms
- The company agreed to sell 30,190 shares of Series A-1 Convertible Preferred Stock for aggregate gross proceeds of $30 million in a private placement to accredited investors.
- Closing was expected on or about March 8, 2023, subject to customary conditions. The filing does not confirm that closing occurred.
- Estimated proceeds were approximately $30 million before placement-agent fees and other offering expenses. EF Hutton is entitled to a cash fee equal to 5.5% of gross proceeds, or approximately $1.65 million if the full offering closes, plus expense reimbursement of up to $75,000.
- The Series A-1 Preferred Stock is subject to an 8% annual compounded dividend before stockholder approval, increasing to 14% if approval is not obtained at the first stockholder meeting following issuance.
- Accrued dividends may be added to the liquidation preference and conversion amounts if not paid in cash.
- The preferred stock has voting rights generally based on an as-converted basis, subject to a pre-approval cap of 19.9% of common stock outstanding as of the signing date.
Material Changes, Conversion Rights, and Potential Dilution
- Conversion of the Series A-1 Preferred Stock into Units requires stockholder approval. Each share is expected to convert automatically on the tenth trading day after the company announces receipt of that approval.
- Each Unit may include common stock or Series A-2 Preferred Stock, plus Tranche A, B, and C warrants.
- Tranche A warrants have an aggregate exercise price of approximately $25 million and become exercisable through 21 days after FDA approval of Renazorb.
- Tranche B warrants have an aggregate exercise price of approximately $25 million and become exercisable through 21 days after TDAPA approval for Renazorb.
- Tranche C warrants have an aggregate exercise price of approximately $50 million and become exercisable through 21 days after four quarters of commercial Renazorb sales following TDAPA approval.
- Series A-2 through Series A-5 Preferred Stock may generally be converted into common stock at the holder’s option, subject to the certificate’s limitations. The transaction could therefore result in substantial future dilution, although the filing does not provide a clear total number of common shares issuable.
- If stockholder approval is not obtained within one year after issuance, holders may request redemption for the then-current liquidation preference during the permitted redemption period, subject to Delaware-law restrictions and the company’s available assets.
Guidance, Outlook, Risks, and Other Matters
- Management intends to use the financing for Renazorb’s NDA submission and potential U.S. commercialization; FDA and TDAPA approvals remain uncertain.
- Following FDA approval and commencement of commercial sales, the company intends to modify its dividend policy so aggregate quarterly dividends equal at least 75% of annual net cash flow from operations, subject to the stated terms.
- The securities were issued or are to be issued without Securities Act registration under private-placement exemptions. There is no established trading market, and the company does not intend to list the preferred stock, warrants, or preferred warrant shares.
- After stockholder approval, the company must file a Form S-3 registration statement for resale of registrable shares within 15 days and use commercially reasonable efforts to obtain effectiveness within 30 days, or 60 days if reviewed by the SEC.
- Upon closing, Gaurav Aggarwal, M.D. is to join the Board of Directors and receive standard non-employee director compensation and an indemnification agreement.
- The filing provides no revenue, profit, cash-flow, margin, debt, or liquidity metrics for the reporting period.
Investor Verification Checklist
- Confirm whether the offering closed and the actual cash proceeds received after fees and expenses.
- Review the Certificate of Designation to determine the precise conversion mechanics, share counts, voting limits, dividend accruals, liquidation preferences, and redemption obligations.
- Quantify potential common-stock dilution from conversion of all preferred stock and exercise of all warrants.
- Verify whether stockholder approval was obtained and whether the required Form S-3 registration statement was filed and declared effective.
- Assess the timing and probability of Renazorb FDA and TDAPA approvals, NDA submission, and commercial launch.
- Evaluate whether the company has sufficient liquidity to meet operating needs and any potential preferred-stock redemption obligations; the 8-K does not provide sufficient information to make that assessment.